| Literature DB >> 33795196 |
Stefano Frara1, Agnese Allora1, Luigi di Filippo1, Anna Maria Formenti1, Paola Loli1, Elisabetta Polizzi2, Daniele Tradati3, Fabio Massimo Ulivieri1, Andrea Giustina4.
Abstract
Pathophysiology and effects of endogenous glucocorticoid (GC) excess on skeletal endpoints as well as awareness and management of bone fragility are reviewed. Cushing's syndrome (CS) increase the risk of fracture affecting prevalently bone quality. Bone antiresorptive agents (SERMs, bisphosphonates and denosumab) as well as teriparatide increase bone mineral density and in some instances reduce fracture risk. Awareness and management of bone health in CS can be improved.Entities:
Keywords: adrenal incidentaloma; bone mineral density; bone quality; cushing disease; fractures; glucocorticoids
Year: 2021 PMID: 33795196 DOI: 10.1016/j.beem.2021.101515
Source DB: PubMed Journal: Best Pract Res Clin Endocrinol Metab ISSN: 1521-690X Impact factor: 4.690